<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Brentuximab vedotin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Brentuximab vedotin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Brentuximab vedotin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="16807" href="/d/html/16807.html" rel="external">see "Brentuximab vedotin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="140333" href="/d/html/140333.html" rel="external">see "Brentuximab vedotin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F13713190"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Progressive multifocal leukoencephalopathy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving brentuximab vedotin.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13204259"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adcetris</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871379"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Adcetris</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13190981"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-CD30;</li>
<li>
                        Antineoplastic Agent, Antibody Drug Conjugate;</li>
<li>
                        Antineoplastic Agent, Antimicrotubular;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F13203262"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="66f9d3e7-f3f2-4b93-9273-e189b3d896fa">Hodgkin lymphoma, advanced, previously untreated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, advanced, previously untreated:</b>
<b>IV:</b> 1.2 mg/kg (maximum dose: 120 mg) every 2 weeks (in combination with doxorubicin, vinblastine, and dacarbazine [AVD]; begin brentuximab within ~1 hour after completion of AVD) until a maximum of 12 doses, disease progression, or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29224502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29224502'])">Ref</a></span>). Administer primary prophylaxis with G-CSF (filgrastim) beginning with cycle 1.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ebbaa33-8ab0-44b8-a662-fd68c7d18267">Hodgkin lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed or refractory:</b>
<b>IV:</b> 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until disease progression or unacceptable toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22454421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22454421'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b34cde8-9b17-4412-8ecc-2a2cb92883b2">Hodgkin lymphoma, consolidation therapy after autologous hematopoietic cell transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, consolidation therapy after autologous hematopoietic cell transplantation (HCT):</b>
<b>IV:</b> 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until a maximum of 16 cycles, disease progression, or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25796459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25796459'])">Ref</a></span>). Begin brentuximab vedotin within 4 to 6 weeks post HCT or upon recovery from HCT.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60aadf0e-258a-429c-b598-cff1505a1eb5">Mycosis fungoides, CD30-expressing, relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycosis fungoides, CD30-expressing, relapsed:</b>
<b>IV:</b> 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until a maximum of 16 cycles, disease progression, or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28600132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28600132'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="84ed9326-bda4-4110-a207-cbd9659211a9">Peripheral T-cell lymphoma, CD30-expressing, previously untreated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral T-cell lymphoma, CD30-expressing, previously untreated: IV: </b>1.8 mg/kg (maximum dose: 180 mg) every 3 weeks for 6 to 8 doses (in combination with cyclophosphamide, doxorubicin, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30522922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30522922'])">Ref</a></span>). Administer primary prophylaxis with G-CSF (filgrastim) beginning with cycle 1.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a7d70aa-f9d7-4d76-b842-9a19693fc781">Primary cutaneous anaplastic large cell lymphoma, relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary cutaneous anaplastic large cell lymphoma, relapsed (pcALCL):</b>
<b>IV:</b> 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until a maximum of 16 cycles, disease progression, or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28600132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28600132'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ba36565-42b8-4ddb-b93e-f67f305ddce6">Systemic anaplastic large cell lymphoma, previously untreated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic anaplastic large cell lymphoma (sALCL), previously untreated: IV: </b>1.8 mg/kg (maximum dose: 180 mg) every 3 weeks for 6 to 8 doses (in combination with cyclophosphamide, doxorubicin, and prednisone).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bb2e814-e241-4bd8-8bdf-e00cd4741edf">Systemic anaplastic large cell lymphoma, relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic anaplastic large cell lymphoma, relapsed:</b>
<b>IV:</b> 1.8 mg/kg (maximum dose: 180 mg) every 3 weeks, continue until disease progression or unacceptable toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22614995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22614995'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991288"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: Initial: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Avoid use.</p></div>
<div class="block doha drugH1Div" id="F50988602"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Usual dose 1.2 mg/kg every 2 weeks: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment (Child-Pugh class A): Initial: 0.9 mg/kg (maximum dose: 90 mg) every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe impairment (Child-Pugh class B or C): Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Usual dose 1.8 mg/kg every 3 weeks: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment (Child-Pugh class A): Initial: 1.2 mg/kg (maximum dose: 120 mg) every 3 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe impairment (Child-Pugh class B or C): Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>New, worsening, or recurrent hepatotoxicity:</i> May require brentuximab vedotin treatment delay, dose modification, or discontinuation.</p></div>
<div class="block doo drugH1Div" id="F57490907"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> According to the prescribing information, the dose for patients weighing &gt;100 kg should be calculated based on a weight of 100 kg (refer to "Dosing: Adult").</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F13203279"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematologic toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Combination therapy (usual dose 1.2 mg/kg every 2 weeks or 1.8 mg/kg every 3 weeks):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 or 4 neutropenia:</i> Administer G-CSF prophylaxis for subsequent cycles for patients not receiving primary prophylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">Single agent therapy (usual dose 1.8 mg/kg every 3 weeks):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 or 4 neutropenia:</i> Withhold treatment until resolves to baseline or ≤ grade 2, consider growth factor support in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Recurrent grade 4 neutropenia (despite the use of growth factor prophylaxis):</i> Consider reducing the dose to 1.2 mg/kg (maximum dose: 120 mg) every 3 weeks or discontinuing treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonhematologic toxicities:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Anaphylaxis:</i> Discontinue brentuximab vedotin immediately and permanently (and administer appropriate medical intervention).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyperglycemia:</i> Administer antihyperglycemics as clinically indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infusion reaction:</i> Interrupt brentuximab vedotin infusion and administer appropriate medical intervention. Premedicate subsequent infusions with acetaminophen, an antihistamine, and/or a corticosteroid.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peripheral neuropathy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Combination therapy (usual dose 1.2 mg/kg every 2 weeks):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Grade 2:</i> Reduce brentuximab vedotin dose to 0.9 mg/kg (maximum dose: 90 mg) every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Grade 3:</i> Withhold treatment until improves or returns to grade 2 or lower; then resume with dose reduced to 0.9 mg/kg (maximum dose: 90 mg) every 2 weeks. Also consider modifying the dose of other neurotoxic chemotherapy agents.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Grade 4:</i> Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Combination therapy (usual dose 1.8 mg/kg every 3 weeks):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Grade 2:</i> For grade 2 sensory neuropathy, continue treatment at the same dose. For grade 2 motor neuropathy, reduce brentuximab vedotin dose to 1.2 mg/kg (maximum dose: 120 mg) every 3 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Grade 3:</i> For grade 3 sensory neuropathy, reduce brentuximab vedotin dose to 1.2 mg/kg (maximum dose: 120 mg) every 3 weeks. For grade 3 motor neuropathy, discontinue brentuximab vedotin.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Grade 4:</i> Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Single agent therapy (usual dose 1.8 mg/kg every 3 weeks):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>New or worsening grade 2 or 3:</i> Withhold treatment until improves or returns to grade 1 or baseline; then resume with dose reduced to 1.2 mg/kg (maximum dose: 120 mg) every 3 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Grade 4:</i> Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Progressive multifocal leukoencephalopathy (PML):</i> Withhold treatment with new-onset symptoms suggestive of PML; discontinue brentuximab vedotin if PML diagnosis confirmed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary toxicity (</i>
<i>new-onset or worsening pulmonary symptoms</i>
<i>):</i> Withhold treatment until symptomatic improvement; perform prompt diagnostic evaluation and management.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Stevens-Johnson syndrome or toxic epidermal necrolysis:</i> Discontinue brentuximab vedotin and administer appropriate medical intervention.</p></div>
<div class="block doe drugH1Div" id="F13203263"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57555725"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="140333" href="/d/html/140333.html" rel="external">see "Brentuximab vedotin: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6c2766a-2a1a-4f67-9f86-c1461b4cfee7">Hodgkin lymphoma, classic; high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, classic; high-risk:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: IV: 1.8 mg/kg/dose; maximum dose: 180 mg/dose; administer every 3 weeks with each cycle of chemotherapy up to 5 doses total. For use in previously untreated patients and administered in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide along with filgrastim. For patients weighing &gt;100 kg, calculate dose based on a weight of 100 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322844','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322844','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hodgkin lymphoma </b></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: IV: <b>Note:</b> Adjustment to the vincristine dose may be necessary in some instances; refer to Vincristine monograph for details.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Brentuximab Dosing Adjustment for Toxicity in Pediatric Patients (Based on Combination Therapy Usual Dose of 1.8 mg/kg Every 3 Weeks)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><tbody valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">Hematologic toxicity</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Neutropenia, grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">In patients unable to start a cycle &gt;5 weeks after the initiation of the previous cycle due to neutropenia (ie, &gt;2-week treatment delay), reduce brentuximab dose to 1.2 mg/kg (maximum dose: 120 mg/dose) every 3 weeks.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">Nonhematologic toxicity</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Peripheral neuropathy: Grade 2</i></p></td>
<td align="left">
<p style="text-indent:0em;">Continue brentuximab at current dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Peripheral neuropathy: Grade 3</i></p></td>
<td align="left">
<p style="text-indent:0em;">First occurrence: Hold brentuximab until improvement to ≤ grade 2; restart at reduced dose of 1.2 mg/kg (maximum dose: 120 mg/dose).</p>
<p style="text-indent:0em;margin-top:2em;">Second occurrence: Hold brentuximab until improvement to ≤ grade 2; restart at reduced dose of 0.8 mg/kg (maximum dose: 80 mg/dose).</p>
<p style="text-indent:0em;margin-top:2em;">Third occurrence: Discontinue brentuximab treatment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<i>Peripheral neuropathy: Grade 4</i></p></td>
<td align="left">
<p style="text-indent:0em;">Discontinue brentuximab treatment.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F57555741"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: Initial: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Avoid use.</p></div>
<div class="block dohp drugH1Div" id="F57555742"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatic impairment at treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment: Reduce initial dose to 1.2 mg/kg (maximum dose: 120 mg/dose) every 3 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe impairment: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">New, worsening, or recurrent hepatotoxicity: May require brentuximab vedotin treatment delay, dose modification, or discontinuation.</p></div>
<div class="block adr drugH1Div" id="F13203240"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults on monotherapy regimens, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (15%), maculopapular rash (11%), pruritus (11% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (14%), constipation (13%), decreased appetite (12% to 15%), diarrhea (20% to 29%; grade 3: 2% to 3%), nausea (22% to 36%; grade 3: 2% to 3%), vomiting (16% to 17%; grade 3: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (27% to 62%; grade 3: 4%), neutropenia (21% to 78%; grades 3/4: 2% to 30%), thrombocytopenia (15% to 41%; grades 3/4: 2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related relation (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (11%), fatigue (24% to 29%), headache (11%), peripheral neuropathy (≤62%; grade 3: 4%; including peripheral motor neuropathy [23%; grade 3: 6%], peripheral sensory neuropathy [45% to 56%; grade 3: 5% to 10%])</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (12% to 18%), muscle spasm (11%), myalgia (11% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (21%), dyspnea (11% to 13%), upper respiratory tract infection (26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (17% to 19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (serious: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (≤8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Severe hepatotoxicity (2%; including increased serum bilirubin, increased serum transaminases)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (serious: 4%), pulmonary toxicity (5%; including acute respiratory distress syndrome, interstitial lung disease, pneumonitis)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (can be neutralizing)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Paresthesia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (monotherapy or combination therapy):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatological: Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Exacerbation of diabetes mellitus, ketoacidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis, enterocolitis, gastrointestinal erosion, gastrointestinal hemorrhage, gastrointestinal perforation, gastrointestinal ulcer, intestinal obstruction, neutropenic enterocolitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacteremia, JC virus infection (resulting in progressive multifocal leukoencephalopathy), opportunistic infection, sepsis, septic shock, serious infection</p></div>
<div class="block coi drugH1Div" id="F13203237"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concurrent use with bleomycin (due to pulmonary toxicity [eg, interstitial infiltration and/or inflammation]).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling (additional contraindications not in the US labeling):</i> Hypersensitivity to brentuximab or any component of the formulation; patients who have or have had progressive multifocal leukoencephalopathy</p></div>
<div class="block war drugH1Div" id="F13203238"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Grade 3 or 4 neutropenia, thrombocytopenia, and anemia may occur. Neutropenia may be severe and/or prolonged (≥1 week). Neutropenic fever (sometimes fatal) also has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported (some fatal).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Acute pancreatitis (some fatal) has been observed. Other serious and fatal GI complications (including hemorrhage, obstruction, perforation, erosion, ulcer, enterocolitis, neutropenic colitis, and ileus) have also been reported. The risk for GI complications may be increased in patients with lymphoma with preexisting GI involvement. Prompt diagnostic evaluation and management should be performed if new or worsening GI symptoms (including severe abdominal pain) occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: The incidence of ≥ grade 3 adverse reactions may be increased in patients with moderate or severe impairment (compared to patients with normal hepatic function).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serious hepatotoxicity, including fatalities, has occurred; cases were consistent with hepatocellular injury, with elevations of transaminases and/or bilirubin. Some have occurred after the initial dose or after rechallenge. The risk for hepatotoxicity may be increased with preexisting liver disease, elevated baseline liver enzymes, and concurrent medications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemia: Hyperglycemia, including new-onset hyperglycemia, exacerbation of pre-existing diabetes mellitus, and ketoacidosis (including fatalities) have been reported, including grade 3 and 4 events. The median time to hyperglycemia onset was 1 month (range: up to 10 months). Hyperglycemia occurred more frequently in patients with increased body mass or diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious infection, including opportunistic infections (eg, pneumonia, bacteremia, sepsis/septic shock) have been reported (some fatal).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions/anaphylaxis: Infusion reactions, including anaphylaxis have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral neuropathy: Peripheral neuropathy is common and is generally cumulative; grades 1 to 4 neuropathy have been reported. Neuropathy is usually sensory, although motor neuropathy has also been observed. Neuropathy completely resolved in over half of patients receiving brentuximab vedotin as monotherapy; almost one-quarter had partial improvement. Neuropathy did not improve in some patients. In patients receiving brentuximab as a single agent, the median time to onset of neuropathy (any grade) was 3 months (range: up to 12 months), and the median time from onset to resolution or improvement of any grade was 5 months (range: up to 45 months). Of patients experiencing ongoing neuropathy, most cases were grade 1, although some patients experienced grade 2 or 3 ongoing neuropathy. In patients receiving brentuximab in combination with chemotherapy, the median time to onset of neuropathy (any grade) was 2 months (range: up to 7 months), with onset for grade 2 neuropathy of 3 months (range: up to 6 months) and grade 3 neuropathy of 4 months (range: up to 7 months). The median time from onset to resolution or improvement of any grade was 4 to ~7 months (range: up to 67 months). Based on an updated analysis, neuropathy completely resolved in a majority of patients receiving brentuximab in combination with chemotherapy; although some patients experienced either partial improvement or no improvement. Of patients experiencing ongoing neuropathy, a majority of cases were grade 1, approximately one fourth of patients had ongoing grade 2 neuropathy, some patients had grade 3 ongoing neuropathy, while a small percentage of patients had grade 4 ongoing neuropathy. Symptoms of neuropathy include hypoesthesia, hyperesthesia, paresthesia, discomfort, burning sensation, neuropathic pain, or weakness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Progressive multifocal leukoencephalopathy: Cases of progressive multifocal leukoencephalopathy (PML) and death due to JC virus infection have been reported. Immunosuppression due to prior chemotherapy treatments or underlying disease may also contribute to PML development. New-onset signs/symptoms of central nervous system abnormalities include changes in mood, memory, cognition, motor incoordination and/or weakness, speech and/or visual disturbances. The time to initial symptom onset varies from treatment initiation, with some cases occurring within 3 months of initial drug exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Noninfectious pulmonary toxicity (eg, pneumonitis, interstitial lung disease, acute respiratory distress syndrome), some fatal, has been reported in patients receiving brentuximab vedotin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Due to higher exposure of monomethylauristatin E (MMAE; the microtubule disrupting agent component), the incidence of ≥ grade 3 adverse reactions may be increased in patients with severe impairment (compared to patients with normal kidney function).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (TLS) may occur; risk of TLS is higher in patients with a high tumor burden or with rapid tumor proliferation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleomycin: Due to the risk for pulmonary injury, concurrent use with bleomycin is contraindicated. In a study comparing brentuximab combined with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) to brentuximab combined with AVD (doxorubicin, vinblastine, and dacarbazine), the occurrence of pulmonary toxicity was higher in the brentuximab/ABVD group. Pulmonary symptoms/toxicities reported with brentuximab in combination with ABVD consisted of cough, dyspnea, and interstitial infiltration/inflammation; most patients responded to corticosteroids.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age may be at higher risk for grade 3 or higher adverse events and neutropenic fever when brentuximab vedotin is used in combination with chemotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F13204260"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adcetris: 50 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F13203233"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322915"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Adcetris Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $13,562.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871380"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adcetris: 50 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F13203282"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Infuse over 30 minutes. Do not administer as IV push or bolus; do not mix or infuse with other medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hodgkin lymphoma (previously untreated):</i> When administering in combination with doxorubicin, vinblastine, and dacarbazine [AVD], begin brentuximab within ~1 hour after completion of AVD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29224502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29224502'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F57555744"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Infuse over 30 minutes. Do not administer as IV push or bolus; do not mix or infuse with other medications. Refer to protocol regarding timing of brentuximab dose in relation to chemotherapy.</p></div>
<div class="block hazard drugH1Div" id="F49130904"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F13190983"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaplastic large cell lymphoma (primary cutaneous), relapsed:</b> Treatment of primary cutaneous anaplastic large cell lymphoma in adults who have received prior systemic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaplastic large cell lymphoma (systemic), previously untreated:</b> Treatment of previously untreated systemic anaplastic large cell lymphoma in adults (in combination with cyclophosphamide, doxorubicin, and prednisone).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaplastic large cell lymphoma (systemic), relapsed:</b> Treatment of systemic anaplastic large cell lymphoma in adults after failure of at least 1 prior multiagent chemotherapy regimen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, previously untreated:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of previously untreated stage III or IV classical Hodgkin lymphoma in adults (in combination with doxorubicin, vinblastine, and dacarbazine).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of previously untreated high risk classical Hodgkin lymphoma in pediatric patients ≥2 years of age (in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed or refractory:</b> Treatment of classical Hodgkin lymphoma in adults after failure of at least 2 prior multiagent chemotherapy regimens (in patients who are not autologous hematopoietic cell transplant [HCT] candidates) or after failure of autologous HCT.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, consolidation (post-autologous hematopoietic cell transplantation):</b> Treatment of classical Hodgkin lymphoma in adults at high risk of relapse or progression as post-autologous HCT consolidation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycosis fungoides, CD30-expressing, relapsed: </b>Treatment of CD30-expressing mycosis fungoides in adults who have received prior systemic therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral T-</b>
<b>cell lymphoma, CD30-expressing, previously untreated: </b>Treatment of previously untreated CD30-expressing peripheral T-cell lymphomas (PTCL) in adults, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (in combination with cyclophosphamide, doxorubicin, and prednisone).</p></div>
<div class="block mst drugH1Div" id="F13190979"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Brentuximab vedotin may be confused with belantamab mafodotin, bendamustine, bevacizumab, bezlotoxumab, polatuzumab vedotin, rituximab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298881"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F13225881"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bleomycin: Brentuximab Vedotin may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095708"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 2 months after the last brentuximab vedotin dose. Patients with partners who could become pregnant should use effective contraception during treatment and for 4 months after the last brentuximab vedotin dose. Brentuximab vedotin treatment may compromise fertility.</p></div>
<div class="block pri drugH1Div" id="F13203235"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and on animal data, in utero exposure to brentuximab vedotin may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F13203236"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if brentuximab vedotin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during brentuximab vedotin treatment.</p></div>
<div class="block mop drugH1Div" id="F13203286"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential prior to each dose (monitor more frequently in patients with grade 3 or 4 neutropenia); liver and renal function tests. Verify pregnancy status (in females of reproductive potential) prior to treatment initiation. Monitor for infusion reaction. Monitor for signs/symptoms of progressive multifocal leukoencephalopathy (evaluate with MRI, and lumbar puncture or brain biopsy), neuropathy (hypoesthesia, hyperesthesia, paresthesia, discomfort, burning sensation, or neuropathic pain or weakness), dermatologic toxicity, pulmonary toxicity (new or worsening symptoms such as cough or dyspnea), GI toxicity, tumor lysis syndrome, and/or infection (bacterial, fungal, or viral).</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F13203253"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Brentuximab vedotin is an antibody drug conjugate (ADC) directed at CD30 consisting of 3 components: 1) a CD30-specific chimeric IgG1 antibody cAC10;  2) a microtubule-disrupting agent, monomethylauristatin E (MMAE); and 3) a protease cleavable dipeptide linker (which covalently conjugates MMAE to cAC10). The conjugate binds to cells which express CD30, and forms a complex which is internalized within the cell and releases MMAE. MMAE binds to the tubules and disrupts the cellular microtubule network, inducing cell cycle arrest (G2/M phase) and apoptosis.</p></div>
<div class="block phk drugH1Div" id="F13203255"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: ADC: ~6 to 10 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: MMAE: 68% to 82%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: MMAE: Minimal, primarily via oxidation by CYP3A4/5</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: ADC: ~4 to 6 days; MMAE: ~3 to 4 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ADC: At end of infusion; MMAE: ~1 to 3 days after the end of infusion</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: MMAE: Feces (~72% [of recovered MMAE], primarily unchanged); urine</p></div>
<div class="block phksp drugH1Div" id="F51154155"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The exposure (AUC) of MMAE, a brentuximab vedotin component, was increased ~2-fold in patients with severe renal impairment receiving a 1.2 mg/kg dose compared to patients with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The exposure (AUC) of MMAE, a brentuximab vedotin component, was increased ~2.3-fold in patients with hepatic impairment receiving a 1.2 mg/kg dose compared to patients with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059495"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adcetris</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adcetris.1">
<a name="Adcetris.1"></a>Adcetris (brentuximab vedotin) [prescribing information]. Bothell, WA: Seagen Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adcetris.2">
<a name="Adcetris.2"></a>Adcetris (brentuximab vedotin) [product monograph]. Mississauga, Ontario, Canada: Seagen Canada Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322844">
<a name="36322844"></a>Castellino SM, Pei Q, Parsons SK, et al. Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma. <i>N Engl J Med</i>. 2022;387(18):1649-1660. doi:10.1056/NEJMoa2206660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/36322844/pubmed" id="36322844" target="_blank">36322844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29224502">
<a name="29224502"></a>Connors JM, Jurczak W, Straus DJ, et al; ECHELON-1 Study Group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma [published correction appears in:<i> N Engl J Med</i>. 2018;378(9):878.]. <i>N Engl J Med</i>. 2018;378(4):331-344. doi:10.1056/NEJMoa1708984<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/29224502/pubmed" id="29224502" target="_blank">29224502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23719719">
<a name="23719719"></a>Han TH, Chen R, Advani R, et al. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. <i>Cancer Chemother Pharmacol</i>. 2013;72(1):241-249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/23719719/pubmed" id="23719719" target="_blank">23719719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23754575">
<a name="23754575"></a>Han TH, Gopal AK, Ramchandren R, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. <i>J Clin Pharmacol</i>. 2013;53(8):866-877.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/23754575/pubmed" id="23754575" target="_blank">23754575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30522922">
<a name="30522922"></a>Horwitz S, O'Connor OA, Pro B, et al; ECHELON-2 study group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i>. 2019;393(10168):229-240. doi:10.1016/S0140-6736(18)32984-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/30522922/pubmed" id="30522922" target="_blank">30522922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25796459">
<a name="25796459"></a>Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in <i>Lancet</i>. 2015;386(9993):532]. <i>Lancet</i>. 2015;385(9980):1853-1862.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/25796459/pubmed" id="25796459" target="_blank">25796459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28600132">
<a name="28600132"></a>Prince HM, Kim YH, Horwitz SM, et al; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i>. 2017;390(10094):555-566. doi:10.1016/S0140-6736(17)31266-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/28600132/pubmed" id="28600132" target="_blank">28600132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22614995">
<a name="22614995"></a>Pro B, Avandi R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>J Clin Oncol</i>. 2012;30(18):2190-2196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/22614995/pubmed" id="22614995" target="_blank">22614995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 19, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21047225">
<a name="21047225"></a>Younes A, Bartlett NL, Leonard JP, et al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. <i>N Engl J Med</i>. 2010;363(19):1812-1821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/21047225/pubmed" id="21047225" target="_blank">21047225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24239220">
<a name="24239220"></a>Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. <i>Lancet Oncol</i>. 2013;14(13):1348-1356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/24239220/pubmed" id="24239220" target="_blank">24239220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22454421">
<a name="22454421"></a>Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>J Clin Oncol</i>. 2012;30(18):2183-2189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/brentuximab-vedotin-drug-information/abstract-text/22454421/pubmed" id="22454421" target="_blank">22454421</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16806 Version 276.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
